25 XP   0   0   10

ProQR Therapeutics BV
Buy, Hold or Sell?

Let's analyze Proqr together

I guess you are interested in ProQR Therapeutics BV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ProQR Therapeutics BV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ProQR Therapeutics BV

I send you an email if I find something interesting about ProQR Therapeutics BV.

Quick analysis of Proqr (30 sec.)










What can you expect buying and holding a share of Proqr? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.46
Expected worth in 1 year
$0.15
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.32
Return On Investment
-19.3%

For what price can you sell your share?

Current Price per Share
$1.64
Expected price per share
$1.58 - $1.78
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Proqr (5 min.)




Live pricePrice per Share (EOD)

$1.64

Intrinsic Value Per Share

$-5.60 - $-5.29

Total Value Per Share

$-5.14 - $-4.83

2. Growth of Proqr (5 min.)




Is Proqr growing?

Current yearPrevious yearGrowGrow %
How rich?$37.6m$74.4m-$27.3m-58.1%

How much money is Proqr making?

Current yearPrevious yearGrowGrow %
Making money-$7.2m-$15.5m$8.3m115.6%
Net Profit Margin-354.8%-1,623.7%--

How much money comes from the company's main activities?

3. Financial Health of Proqr (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Proqr? (5 min.)

Welcome investor! Proqr's management wants to use your money to grow the business. In return you get a share of Proqr.

What can you expect buying and holding a share of Proqr?

First you should know what it really means to hold a share of Proqr. And how you can make/lose money.

Speculation

The Price per Share of Proqr is $1.64. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Proqr.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Proqr, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.46. Based on the TTM, the Book Value Change Per Share is $-0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Proqr.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-6.2%-0.09-5.4%-0.19-11.8%-0.17-10.1%-0.16-9.6%
Usd Book Value Change Per Share-0.09-5.3%-0.08-4.8%-0.18-11.0%-0.03-1.9%0.010.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.09-5.3%-0.08-4.8%-0.18-11.0%-0.03-1.9%0.010.7%
Usd Price Per Share2.29-1.80-1.84-4.53-7.25-
Price to Earnings Ratio-5.61--5.18--3.18--7.62--2.47-
Price-to-Total Gains Ratio-26.31--23.18-114.44--5.74--56.27-
Price to Book Ratio4.96-3.27-2.14-4.69-7.51-
Price-to-Total Gains Ratio-26.31--23.18-114.44--5.74--56.27-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.64
Number of shares609
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.08-0.03
Usd Total Gains Per Share-0.08-0.03
Gains per Quarter (609 shares)-48.09-18.53
Gains per Year (609 shares)-192.34-74.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-192-2020-74-84
20-385-3940-148-158
30-577-5860-222-232
40-769-7780-297-306
50-962-9700-371-380
60-1154-11620-445-454
70-1346-13540-519-528
80-1539-15460-593-602
90-1731-17380-667-676
100-1923-19300-741-750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%2.041.01.04.5%
Book Value Change Per Share0.04.00.00.0%3.08.01.025.0%4.015.01.020.0%8.030.02.020.0%9.031.04.020.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.044.00.0%
Total Gains per Share0.04.00.00.0%3.08.01.025.0%4.015.01.020.0%8.030.02.020.0%9.031.04.020.5%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Proqr

About ProQR Therapeutics BV

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Fundamental data was last updated by Penke on 2024-06-19 04:32:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of ProQR Therapeutics BV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Proqr earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Proqr to the Biotechnology industry mean.
  • A Net Profit Margin of -172.1% means that $-1.72 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ProQR Therapeutics BV:

  • The MRQ is -172.1%. The company is making a huge loss. -2
  • The TTM is -354.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-172.1%TTM-354.8%+182.7%
TTM-354.8%YOY-1,623.7%+1,269.0%
TTM-354.8%5Y-1,878.9%+1,524.1%
5Y-1,878.9%10Y-3,556.6%+1,677.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-172.1%-168.0%-4.1%
TTM-354.8%-209.9%-144.9%
YOY-1,623.7%-242.3%-1,381.4%
5Y-1,878.9%-401.7%-1,477.2%
10Y-3,556.6%-532.2%-3,024.4%
1.1.2. Return on Assets

Shows how efficient Proqr is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Proqr to the Biotechnology industry mean.
  • -6.2% Return on Assets means that Proqr generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ProQR Therapeutics BV:

  • The MRQ is -6.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.2%TTM-4.9%-1.3%
TTM-4.9%YOY-9.9%+5.0%
TTM-4.9%5Y-9.8%+4.9%
5Y-9.8%10Y-11.2%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.2%-11.9%+5.7%
TTM-4.9%-11.9%+7.0%
YOY-9.9%-11.3%+1.4%
5Y-9.8%-13.5%+3.7%
10Y-11.2%-14.9%+3.7%
1.1.3. Return on Equity

Shows how efficient Proqr is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Proqr to the Biotechnology industry mean.
  • -22.1% Return on Equity means Proqr generated $-0.22 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ProQR Therapeutics BV:

  • The MRQ is -22.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.1%TTM-15.7%-6.4%
TTM-15.7%YOY-21.0%+5.3%
TTM-15.7%5Y-17.6%+2.0%
5Y-17.6%10Y-16.9%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.1%-14.2%-7.9%
TTM-15.7%-15.7%+0.0%
YOY-21.0%-14.3%-6.7%
5Y-17.6%-19.2%+1.6%
10Y-16.9%-19.7%+2.8%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of ProQR Therapeutics BV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Proqr is operating .

  • Measures how much profit Proqr makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Proqr to the Biotechnology industry mean.
  • An Operating Margin of -186.2% means the company generated $-1.86  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ProQR Therapeutics BV:

  • The MRQ is -186.2%. The company is operating very inefficient. -2
  • The TTM is -463.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-186.2%TTM-463.6%+277.4%
TTM-463.6%YOY-1,632.7%+1,169.1%
TTM-463.6%5Y-1,788.4%+1,324.8%
5Y-1,788.4%10Y-3,563.9%+1,775.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-186.2%-354.6%+168.4%
TTM-463.6%-225.9%-237.7%
YOY-1,632.7%-252.2%-1,380.5%
5Y-1,788.4%-428.3%-1,360.1%
10Y-3,563.9%-531.1%-3,032.8%
1.2.2. Operating Ratio

Measures how efficient Proqr is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.86 means that the operating costs are $2.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ProQR Therapeutics BV:

  • The MRQ is 2.862. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.295. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.862TTM5.295-2.433
TTM5.295YOY17.504-12.209
TTM5.2955Y21.395-16.100
5Y21.39510Y32,339,352.544-32,339,331.149
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8623.004-0.142
TTM5.2953.332+1.963
YOY17.5043.502+14.002
5Y21.3955.271+16.124
10Y32,339,352.5446.915+32,339,345.629
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of ProQR Therapeutics BV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Proqr is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.11 means the company has $3.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ProQR Therapeutics BV:

  • The MRQ is 3.113. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.259. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.113TTM4.259-1.146
TTM4.259YOY6.341-2.081
TTM4.2595Y7.215-2.956
5Y7.21510Y11.431-4.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1133.767-0.654
TTM4.2594.000+0.259
YOY6.3414.905+1.436
5Y7.2155.883+1.332
10Y11.4316.286+5.145
1.3.2. Quick Ratio

Measures if Proqr is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Proqr to the Biotechnology industry mean.
  • A Quick Ratio of 3.57 means the company can pay off $3.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ProQR Therapeutics BV:

  • The MRQ is 3.570. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.335. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.570TTM4.335-0.765
TTM4.335YOY6.213-1.878
TTM4.3355Y7.033-2.698
5Y7.03310Y11.203-4.170
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5703.054+0.516
TTM4.3353.506+0.829
YOY6.2134.756+1.457
5Y7.0335.757+1.276
10Y11.2036.338+4.865
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of ProQR Therapeutics BV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Proqr assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Proqr to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.72 means that Proqr assets are financed with 71.9% credit (debt) and the remaining percentage (100% - 71.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ProQR Therapeutics BV:

  • The MRQ is 0.719. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.686. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.719TTM0.686+0.033
TTM0.686YOY0.558+0.128
TTM0.6865Y0.442+0.244
5Y0.44210Y0.305+0.137
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7190.330+0.389
TTM0.6860.342+0.344
YOY0.5580.287+0.271
5Y0.4420.368+0.074
10Y0.3050.382-0.077
1.4.2. Debt to Equity Ratio

Measures if Proqr is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Proqr to the Biotechnology industry mean.
  • A Debt to Equity ratio of 255.8% means that company has $2.56 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ProQR Therapeutics BV:

  • The MRQ is 2.558. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.204. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.558TTM2.204+0.353
TTM2.204YOY1.310+0.894
TTM2.2045Y1.010+1.194
5Y1.01010Y0.614+0.396
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5580.365+2.193
TTM2.2040.415+1.789
YOY1.3100.370+0.940
5Y1.0100.443+0.567
10Y0.6140.476+0.138
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of ProQR Therapeutics BV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Proqr generates.

  • Above 15 is considered overpriced but always compare Proqr to the Biotechnology industry mean.
  • A PE ratio of -5.61 means the investor is paying $-5.61 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ProQR Therapeutics BV:

  • The EOD is -4.019. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.612. Based on the earnings, the company is expensive. -2
  • The TTM is -5.183. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.019MRQ-5.612+1.593
MRQ-5.612TTM-5.183-0.429
TTM-5.183YOY-3.182-2.001
TTM-5.1835Y-7.622+2.439
5Y-7.62210Y-2.472-5.150
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.019-2.341-1.678
MRQ-5.612-2.997-2.615
TTM-5.183-2.882-2.301
YOY-3.182-3.553+0.371
5Y-7.622-6.262-1.360
10Y-2.472-6.288+3.816
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ProQR Therapeutics BV:

  • The EOD is -1.940. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.709. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.296. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.940MRQ-2.709+0.769
MRQ-2.709TTM-3.296+0.587
TTM-3.296YOY-1.223-2.073
TTM-3.2965Y-4.484+1.188
5Y-4.48410Y-16.664+12.180
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.940-2.932+0.992
MRQ-2.709-3.739+1.030
TTM-3.296-3.776+0.480
YOY-1.223-4.917+3.694
5Y-4.484-7.942+3.458
10Y-16.664-8.503-8.161
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Proqr is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.96 means the investor is paying $4.96 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ProQR Therapeutics BV:

  • The EOD is 3.553. Based on the equity, the company is fair priced.
  • The MRQ is 4.961. Based on the equity, the company is fair priced.
  • The TTM is 3.266. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.553MRQ4.961-1.408
MRQ4.961TTM3.266+1.695
TTM3.266YOY2.144+1.122
TTM3.2665Y4.693-1.427
5Y4.69310Y7.505-2.812
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.5531.843+1.710
MRQ4.9612.249+2.712
TTM3.2662.301+0.965
YOY2.1442.412-0.268
5Y4.6933.782+0.911
10Y7.5054.212+3.293
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ProQR Therapeutics BV.

3.1. Institutions holding ProQR Therapeutics BV

Institutions are holding 39.049% of the shares of ProQR Therapeutics BV.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Privium Fund Management B.V.6.54463.2684534444600
2024-03-31Adage Capital Partners Gp LLC4.43960.0157362546700
2024-03-31EcoR1 Capital, LLC3.53210.16712884357-95659-3.21
2024-03-31M28 Capital Management LP1.24841.7251019498-891102-46.6399
2024-03-31Dafna Capital Management LLC1.10890.4721905582-35000-3.7211
2024-03-31Macquarie Group Ltd0.75920.001662000000
2024-03-31Ikarian Capital, LLC0.59220.1204483583109582.3185
2024-03-31Deutsche Bank AG0.47160.0004385149-59-0.0153
2024-03-31Millennium Management LLC0.40290.0003328989-120073-26.7386
2024-03-31Monaco Asset Management0.38280.2124312629-65847-17.3979
2024-03-31Two Sigma Advisers, LLC0.19840.0009162000-6700-3.9715
2024-03-31Squarepoint Ops LLC0.18670.00061525022432818.9804
2024-03-31Franklin Street Advisors Inc.0.18370.025415000000
2024-03-31Susquehanna International Group, LLP0.17160.0001140151126184903.4438
2024-03-31Bank of America Corp0.134801101073185440.7064
2024-03-31BOOTHBAY FUND MANAGEMENT, LLC0.13070.00471067031095811.445
2024-03-31Two Sigma Investments LLC0.09670.000478944-20547-20.6521
2024-03-31Morgan Stanley - Brokerage Accounts0.0828067591-46120-40.559
2024-03-31Geode Capital Management, LLC0.057204667100
2024-03-31Resources Investment Advisors Inc0.05510.0016450001305040.8451
Total 20.786.017116969369-1063775-6.3%

3.2. Funds holding ProQR Therapeutics BV

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Beleggingsfonds Hoofbosch0.97960.520880000000
2024-04-30Delaware Healthcare I0.75920.159362000000
2024-04-30Xtrackers MSCI World Swap ETF 1C0.4020.01132830500
2024-04-30Xtrackers S&P 500 Swap ETF 1C0.06960.00125684400
2024-04-30Fidelity Nasdaq Composite Index0.05720.00064667100
2024-03-31Northern Small Cap Core I0.00760.0029617200
2023-12-31Blackstone Alternative Multi-Strategy I0.00510.00024200-100-2.3256
2024-03-31NT Quality Small Cap Core0.00460.0036379500
2024-03-31NT Quality SCC US Fund - L0.00460.0035379500
2024-04-30LUX IM Global Medtech HX0.0020.0016161200
2024-05-31Avantis International Small Cp Eq ETF0.00020.00218500
2024-03-31Lazard Genetic Therapies ADR0.00010.40510300
Total 2.29181.11171871682-1000.0%
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of ProQR Therapeutics BV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.087-0.079-9%-0.181+107%-0.030-65%0.012-852%
Book Value Per Share--0.4620.576-20%0.912-49%0.980-53%0.953-52%
Current Ratio--3.1134.259-27%6.341-51%7.215-57%11.431-73%
Debt To Asset Ratio--0.7190.686+5%0.558+29%0.442+63%0.305+135%
Debt To Equity Ratio--2.5582.204+16%1.310+95%1.010+153%0.614+316%
Dividend Per Share----0%-0%-0%-0%
Eps---0.102-0.089-13%-0.194+90%-0.166+63%-0.158+54%
Free Cash Flow Per Share---0.211-0.142-33%-0.013-94%-0.099-53%-0.101-52%
Free Cash Flow To Equity Per Share---0.217-0.150-31%-0.114-47%0.030-822%0.043-608%
Gross Profit Margin--1.0881.061+3%1.000+9%1.012+7%1.006+8%
Intrinsic Value_10Y_max---5.294--------
Intrinsic Value_10Y_min---5.598--------
Intrinsic Value_1Y_max---0.296--------
Intrinsic Value_1Y_min---0.432--------
Intrinsic Value_3Y_max---1.067--------
Intrinsic Value_3Y_min---1.418--------
Intrinsic Value_5Y_max---2.055--------
Intrinsic Value_5Y_min---2.527--------
Market Cap133926008.000-40%186998271.780146785762.945+27%150088998.935+25%369549220.148-49%592268988.074-68%
Net Profit Margin---1.721-3.548+106%-16.237+844%-18.789+992%-35.566+1967%
Operating Margin---1.862-4.636+149%-16.327+777%-17.884+861%-35.639+1814%
Operating Ratio--2.8625.295-46%17.504-84%21.395-87%32339352.544-100%
Pb Ratio3.553-40%4.9613.266+52%2.144+131%4.693+6%7.505-34%
Pe Ratio-4.019+28%-5.612-5.183-8%-3.182-43%-7.622+36%-2.472-56%
Price Per Share1.640-40%2.2901.797+27%1.838+25%4.525-49%7.253-68%
Price To Free Cash Flow Ratio-1.940+28%-2.709-3.296+22%-1.223-55%-4.484+66%-16.664+515%
Price To Total Gains Ratio-18.846+28%-26.314-23.184-12%114.438-123%-5.743-78%-56.267+114%
Quick Ratio--3.5704.335-18%6.213-43%7.033-49%11.203-68%
Return On Assets---0.062-0.049-22%-0.099+59%-0.098+58%-0.112+80%
Return On Equity---0.221-0.157-29%-0.210-5%-0.176-20%-0.169-24%
Total Gains Per Share---0.087-0.079-9%-0.181+107%-0.030-65%0.012-852%
Usd Book Value--37693813.66847076991.214-20%74441808.000-49%80014204.143-53%77845191.084-52%
Usd Book Value Change Per Share---0.087-0.079-9%-0.181+107%-0.030-65%0.012-852%
Usd Book Value Per Share--0.4620.576-20%0.912-49%0.980-53%0.953-52%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.102-0.089-13%-0.194+90%-0.166+63%-0.158+54%
Usd Free Cash Flow---17257907.552-11572507.475-33%-1058788.500-94%-8089657.420-53%-8220094.647-52%
Usd Free Cash Flow Per Share---0.211-0.142-33%-0.013-94%-0.099-53%-0.101-52%
Usd Free Cash Flow To Equity Per Share---0.217-0.150-31%-0.114-47%0.030-822%0.043-608%
Usd Market Cap133926008.000-40%186998271.780146785762.945+27%150088998.935+25%369549220.148-49%592268988.074-68%
Usd Price Per Share1.640-40%2.2901.797+27%1.838+25%4.525-49%7.253-68%
Usd Profit---8330878.857-7232096.487-13%-15593607.750+87%-13689269.672+64%-11362952.574+36%
Usd Revenue--4841003.8112771595.469+75%934956.750+418%945551.719+412%1179951.146+310%
Usd Total Gains Per Share---0.087-0.079-9%-0.181+107%-0.030-65%0.012-852%
 EOD+3 -5MRQTTM+9 -25YOY+18 -165Y+10 -2410Y+13 -21

4.2. Fundamental Score

Let's check the fundamental score of ProQR Therapeutics BV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.019
Price to Book Ratio (EOD)Between0-13.553
Net Profit Margin (MRQ)Greater than0-1.721
Operating Margin (MRQ)Greater than0-1.862
Quick Ratio (MRQ)Greater than13.570
Current Ratio (MRQ)Greater than13.113
Debt to Asset Ratio (MRQ)Less than10.719
Debt to Equity Ratio (MRQ)Less than12.558
Return on Equity (MRQ)Greater than0.15-0.221
Return on Assets (MRQ)Greater than0.05-0.062
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of ProQR Therapeutics BV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.063
Ma 20Greater thanMa 501.742
Ma 50Greater thanMa 1001.867
Ma 100Greater thanMa 2002.004
OpenGreater thanClose1.630
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets123,991
Total Liabilities89,138
Total Stockholder Equity34,853
 As reported
Total Liabilities 89,138
Total Stockholder Equity+ 34,853
Total Assets = 123,991

Assets

Total Assets123,991
Total Current Assets107,254
Long-term Assets16,736
Total Current Assets
Cash And Cash Equivalents 85,792
Short-term Investments 17,016
Net Receivables 3,155
Inventory 0
Other Current Assets 1,291
Total Current Assets  (as reported)107,254
Total Current Assets  (calculated)107,254
+/-0
Long-term Assets
Property Plant Equipment 16,736
Long-term Assets  (as reported)16,736
Long-term Assets  (calculated)16,736
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities34,451
Long-term Liabilities54,687
Total Stockholder Equity34,853
Total Current Liabilities
Short-term Debt 4,391
Short Long Term Debt 4,365
Accounts payable 331
Other Current Liabilities 9,142
Total Current Liabilities  (as reported)34,451
Total Current Liabilities  (calculated)18,230
+/- 16,221
Long-term Liabilities
Capital Lease Obligations 14,861
Long-term Liabilities  (as reported)54,687
Long-term Liabilities  (calculated)14,861
+/- 39,826
Total Stockholder Equity
Common Stock3,373
Retained Earnings -408,568
Accumulated Other Comprehensive Income 26,610
Other Stockholders Equity 413,439
Total Stockholder Equity (as reported)34,853
Total Stockholder Equity (calculated)34,853
+/-0
Other
Capital Stock3,370
Cash and Short Term Investments 102,808
Common Stock Shares Outstanding 81,571
Current Deferred Revenue20,586
Liabilities and Stockholders Equity 123,991
Net Debt -68,016
Net Invested Capital 39,186
Net Working Capital 72,736
Short Long Term Debt Total 17,776



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302012-12-31
> Total Assets 
446
0
4,504
0
39,101
116,628
115,247
115,247
111,033
104,778
100,109
91,396
83,933
72,820
65,543
58,127
48,386
45,594
53,103
42,267
37,541
118,991
110,231
101,623
90,252
81,064
117,535
103,634
93,500
110,192
98,729
91,609
162,357
195,331
209,579
209,579
179,053
121,733
171,321
158,012
147,990
142,034
137,997
123,991
123,991137,997142,034147,990158,012171,321121,733179,053209,579209,579195,331162,35791,60998,729110,19293,500103,634117,53581,06490,252101,623110,231118,99137,54142,26753,10345,59448,38658,12765,54372,82083,93391,396100,109104,778111,033115,247115,247116,62839,10104,5040446
   > Total Current Assets 
0
0
4,261
0
38,647
115,857
113,897
113,897
108,830
102,645
97,769
88,478
80,147
69,073
62,015
54,862
45,345
42,802
50,559
39,959
35,294
116,887
108,367
97,698
86,059
78,072
114,666
101,048
91,155
92,158
80,021
72,866
143,584
177,059
191,483
191,483
161,059
104,105
154,460
141,611
131,149
124,687
121,086
107,254
107,254121,086124,687131,149141,611154,460104,105161,059191,483191,483177,059143,58472,86680,02192,15891,155101,048114,66678,07286,05997,698108,367116,88735,29439,95950,55942,80245,34554,86262,01569,07380,14788,47897,769102,645108,830113,897113,897115,85738,64704,26100
       Cash And Cash Equivalents 
328
0
4,129
0
38,193
115,257
112,736
112,736
106,382
100,012
94,865
85,467
76,311
64,921
59,200
52,111
42,321
39,742
48,099
38,001
32,968
113,716
105,580
94,080
82,464
74,792
111,950
98,063
87,141
88,847
75,838
67,878
139,442
156,141
187,524
187,524
156,402
100,431
94,775
138,986
128,562
120,552
119,023
85,792
85,792119,023120,552128,562138,98694,775100,431156,402187,524187,524156,141139,44267,87875,83888,84787,14198,063111,95074,79282,46494,080105,580113,71632,96838,00148,09939,74242,32152,11159,20064,92176,31185,46794,865100,012106,382112,736112,736115,25738,19304,1290328
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,016
17,0160000000000000000000000000000000000000000000
       Net Receivables 
0
0
130
0
454
600
426
426
744
845
956
533
651
490
395
387
738
777
396
993
1,014
1,195
1,243
1,530
1,430
830
850
998
452
552
421
454
381
511
555
555
498
570
57,236
457
400
3,165
1,269
3,155
3,1551,2693,16540045757,2365704985555555113814544215524529988508301,4301,5301,2431,1951,014993396777738387395490651533956845744426426600454013000
       Inventory 
0
0
0
0
0
0
327
327
0
0
547
0
0
0
1,170
0
0
0
73
0
0
0
899
0
0
0
340
0
0
0
379
0
0
0
268
268
0
0
7
-5
-1
-2
0
0
00-2-1-5700268268000379000340000899000730001,17000054700327327000000
   > Long-term Assets 
0
0
243
0
454
771
1,350
1,350
2,203
2,133
2,340
2,918
3,786
3,747
3,528
3,265
3,041
2,792
2,544
2,308
2,247
2,104
1,864
3,925
4,193
2,992
2,869
2,586
2,345
18,034
18,708
18,743
18,773
18,272
18,096
18,096
17,994
17,628
16,861
16,401
16,841
17,347
16,911
16,736
16,73616,91117,34716,84116,40116,86117,62817,99418,09618,09618,27218,77318,74318,70818,0342,3452,5862,8692,9924,1933,9251,8642,1042,2472,3082,5442,7923,0413,2653,5283,7473,7862,9182,3402,1332,2031,3501,350771454024300
       Property Plant Equipment 
0
0
204
0
415
732
1,187
1,187
2,037
1,980
2,199
2,790
3,670
3,644
3,438
3,187
2,976
2,740
2,505
2,269
2,208
2,065
1,864
3,925
3,495
2,413
2,440
2,291
2,102
17,875
18,601
18,122
17,928
17,559
17,467
17,467
17,373
17,007
16,240
15,780
16,220
17,347
16,911
16,736
16,73616,91117,34716,22015,78016,24017,00717,37317,46717,46717,55917,92818,12218,60117,8752,1022,2912,4402,4133,4953,9251,8642,0652,2082,2692,5052,7402,9763,1873,4383,6443,6702,7902,1991,9802,0371,1871,187732415020400
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
698
579
429
295
243
159
107
621
845
713
629
621
621
621
621
621
621
0
0
0
000621621621621621621629713845621107159243295429579698000000000000000000000000
       Intangible Assets 
52
0
39
0
39
39
163
163
166
153
141
128
116
103
90
78
65
52
39
39
39
39
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000039393939526578901031161281411531661631633939039052
       Long-term Assets Other 
0
0
0
0
0
732
1,187
1,747
2,037
1,980
2,199
2,790
3,670
3,644
3,438
3,187
2,976
2,740
2,505
2,269
2,208
2,065
1,864
3,925
3,495
2,413
-1,368
2,291
2,102
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,1022,291-1,3682,4133,4953,9251,8642,0652,2082,2692,5052,7402,9763,1873,4383,6443,6702,7902,1991,9802,0371,7471,18773200000
> Total Liabilities 
315
0
4,593
0
5,079
5,426
5,843
5,843
9,393
9,147
10,310
11,200
13,000
11,386
12,407
12,390
11,604
12,855
13,778
12,814
14,810
16,589
17,546
20,811
20,018
21,645
23,702
22,284
13,932
42,100
42,183
42,429
44,814
67,310
96,350
96,350
92,079
57,193
106,208
99,311
96,490
95,694
96,573
89,138
89,13896,57395,69496,49099,311106,20857,19392,07996,35096,35067,31044,81442,42942,18342,10013,93222,28423,70221,64520,01820,81117,54616,58914,81012,81413,77812,85511,60412,39012,40711,38613,00011,20010,3109,1479,3935,8435,8435,4265,07904,5930315
   > Total Current Liabilities 
189
0
3,602
0
2,364
2,634
3,014
3,014
5,161
4,813
5,486
6,058
7,733
7,761
6,710
6,550
5,519
6,372
8,494
7,087
8,786
10,264
8,160
9,695
9,051
11,135
10,993
9,153
9,033
10,817
10,301
10,494
12,374
34,688
27,596
27,596
27,139
26,972
21,112
17,160
22,976
26,649
34,231
34,451
34,45134,23126,64922,97617,16021,11226,97227,13927,59627,59634,68812,37410,49410,30110,8179,0339,15310,99311,1359,0519,6958,16010,2648,7867,0878,4946,3725,5196,5506,7107,7617,7336,0585,4864,8135,1613,0143,0142,6342,36403,6020189
       Short-term Debt 
0
0
2,549
0
34
15
34
34
29
22
15
7
5,000
1,768
5,697
5,840
203
348
1,960
2,000
2,000
2,000
7
1,262
1,357
1,150
851
825
702
2,257
2,395
2,358
2,945
3,186
6,305
6,305
8,592
3,258
3,887
4,086
4,254
3,824
1,615
4,391
4,3911,6153,8244,2544,0863,8873,2588,5926,3056,3053,1862,9452,3582,3952,2577028258511,1501,3571,26272,0002,0002,0001,9603482035,8405,6971,7685,00071522293434153402,54900
       Short Long Term Debt 
0
0
3,540
0
0
0
2,863
0
0
0
4,839
0
5,000
5,393
5,697
5,840
6,085
6,483
1,960
2,460
2,328
2,315
0
95
178
260
343
519
656
949
1,135
1,337
1,562
1,791
4,771
6,394
7,214
1,888
2,500
2,576
2,920
2,344
0
4,365
4,36502,3442,9202,5762,5001,8887,2146,3944,7711,7911,5621,3371,1359496565193432601789502,3152,3282,4601,9606,4836,0855,8405,6975,3935,00004,8390002,8630003,54000
       Accounts payable 
126
0
745
0
886
1,103
1,247
1,247
893
98
885
1,026
1,038
237
328
177
224
250
546
147
219
771
135
64
188
668
445
578
492
291
221
275
276
894
191
191
767
425
392
276
119
117
1,542
331
3311,542117119276392425767191191894276275221291492578445668188641357712191475462502241773282371,0381,026885988931,2471,2471,10388607450126
       Other Current Liabilities 
63
0
262
0
1,288
1,223
1,265
1,265
2,669
3,993
4,442
4,841
6,695
5,415
6,382
6,373
4,363
5,117
5,641
4,593
4,209
6,371
7,473
8,352
7,324
8,333
8,986
7,193
6,786
7,406
6,985
7,291
7,494
10,621
15,985
15,985
10,956
14,665
11,068
6,963
5,466
6,299
10,488
9,142
9,14210,4886,2995,4666,96311,06814,66510,95615,98515,98510,6217,4947,2916,9857,4066,7867,1938,9868,3337,3248,3527,4736,3714,2094,5935,6415,1174,3636,3736,3825,4156,6954,8414,4423,9932,6691,2651,2651,2231,2880262063
   > Long-term Liabilities 
0
0
991
0
2,715
2,792
2,829
2,829
4,232
4,334
4,824
5,142
5,267
3,625
5,697
5,840
6,085
6,483
5,284
5,727
6,024
6,325
9,386
11,116
10,967
10,510
12,709
13,131
4,899
31,283
31,882
31,935
32,440
32,622
68,754
68,754
64,940
30,221
85,096
82,151
73,514
69,045
62,341
54,687
54,68762,34169,04573,51482,15185,09630,22164,94068,75468,75432,62232,44031,93531,88231,2834,89913,13112,70910,51010,96711,1169,3866,3256,0245,7275,2846,4836,0855,8405,6973,6255,2675,1424,8244,3344,2322,8292,8292,7922,715099100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,165
10,208
10,358
10,510
12,709
13,131
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000013,13112,70910,51010,35810,20814,1650000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-2,549
0
-34
-15
-34
-34
-29
-22
-15
-7
-5,000
-1,768
-5,697
-5,840
-203
-348
-1,960
-2,000
-2,000
-2,000
-7
813
431
-260
-343
-519
-656
13,757
14,558
14,092
13,906
13,318
9,977
9,401
7,349
12,302
11,313
10,855
10,780
12,212
13,827
10,470
10,47013,82712,21210,78010,85511,31312,3027,3499,4019,97713,31813,90614,09214,55813,757-656-519-343-260431813-7-2,000-2,000-2,000-1,960-348-203-5,840-5,697-1,768-5,000-7-15-22-29-34-34-15-340-2,54900
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
908
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000090800000000000000000000000
> Total Stockholder Equity
131
0
-89
0
34,022
111,202
109,404
109,404
101,640
95,631
89,799
80,196
70,933
61,434
53,136
45,737
36,782
32,749
39,363
29,549
22,871
102,575
92,915
81,129
70,633
59,871
94,329
81,869
80,094
68,626
57,091
49,736
118,106
128,606
113,833
113,833
87,369
64,921
65,497
59,007
51,790
46,340
41,424
34,853
34,85341,42446,34051,79059,00765,49764,92187,369113,833113,833128,606118,10649,73657,09168,62680,09481,86994,32959,87170,63381,12992,915102,57522,87129,54939,36332,74936,78245,73753,13661,43470,93380,19689,79995,631101,640109,404109,404111,20234,0220-890131
   Common Stock
44
0
59
0
144
934
934
934
934
934
934
934
934
934
934
955
964
1,019
1,457
1,457
1,457
1,722
1,726
1,726
1,726
1,726
2,159
2,159
2,163
2,163
2,165
2,193
2,830
2,995
2,995
2,995
2,988
2,994
3,370
3,378
3,370
3,370
3,373
3,373
3,3733,3733,3703,3703,3783,3702,9942,9882,9952,9952,9952,8302,1932,1652,1632,1632,1592,1591,7261,7261,7261,7261,7221,4571,4571,4571,019964955934934934934934934934934934934144059044
   Retained Earnings Total Equity00000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
41
0
269
447
687
687
1,306
1,606
1
6
1
1
-15
-13
50
99
136
110
125
121
108
120
82
229
151
407
272
17
-189
0
0
0
30,299
30,299
32,416
34,056
30,264
27,155
1,000
1,286
25,997
26,610
26,61025,9971,2861,00027,15530,26434,05632,41630,29930,299000-18917272407151229821201081211251101369950-13-1511611,6061,30668768744726904100
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
358,392
237,541
237,634
237,636
289,373
289,842
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000289,842289,373237,636237,634237,541358,3920000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
3,482
0
43,995
123,582
123,581
123,581
123,587
123,595
125,494
126,084
126,785
127,413
127,950
131,008
133,344
139,718
148,763
158,011
158,674
244,076
235,744
248,834
249,934
251,156
287,214
306,798
309,054
311,011
288,757
49,736
118,106
128,606
398,309
398,309
87,369
64,921
412,540
413,401
439,352
437,416
413,234
413,439
413,439413,234437,416439,352413,401412,54064,92187,369398,309398,309128,606118,10649,736288,757311,011309,054306,798287,214251,156249,934248,834235,744244,076158,674158,011148,763139,718133,344131,008127,950127,413126,785126,084125,494123,595123,587123,581123,581123,58243,99503,48200



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue6,380
Cost of Revenue-0
Gross Profit6,3806,380
 
Operating Income (+$)
Gross Profit6,380
Operating Expense-38,074
Operating Income-34,155-31,694
 
Operating Expense (+$)
Research Development22,679
Selling General Administrative16,236
Selling And Marketing Expenses841
Operating Expense38,07439,757
 
Net Interest Income (+$)
Interest Income2,593
Interest Expense-1,148
Other Finance Cost-55
Net Interest Income1,390
 
Pretax Income (+$)
Operating Income-34,155
Net Interest Income1,390
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-27,243-41,068
EBIT - interestExpense = -35,303
-27,619
-26,395
Interest Expense1,148
Earnings Before Interest and Taxes (EBIT)-34,155-26,095
Earnings Before Interest and Taxes (EBITDA)-31,694
 
After tax Income (+$)
Income Before Tax-27,243
Tax Provision--78
Net Income From Continuing Ops-27,735-27,165
Net Income-27,543
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses40,536
Total Other Income/Expenses Net6,912-1,390
 

Technical Analysis of Proqr
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Proqr. The general trend of Proqr is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Proqr's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ProQR Therapeutics BV.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.7 < 1.77 < 1.78.

The bearish price targets are: 1.64 > 1.61 > 1.58.

Tweet this
ProQR Therapeutics BV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ProQR Therapeutics BV. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ProQR Therapeutics BV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ProQR Therapeutics BV. The current macd is -0.07375237.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Proqr price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Proqr. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Proqr price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
ProQR Therapeutics BV Daily Moving Average Convergence/Divergence (MACD) ChartProQR Therapeutics BV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ProQR Therapeutics BV. The current adx is 19.27.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Proqr shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
ProQR Therapeutics BV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ProQR Therapeutics BV. The current sar is 1.79499271.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
ProQR Therapeutics BV Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ProQR Therapeutics BV. The current rsi is 31.06. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
ProQR Therapeutics BV Daily Relative Strength Index (RSI) ChartProQR Therapeutics BV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ProQR Therapeutics BV. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Proqr price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
ProQR Therapeutics BV Daily Stochastic Oscillator ChartProQR Therapeutics BV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ProQR Therapeutics BV. The current cci is -69.63995273.

ProQR Therapeutics BV Daily Commodity Channel Index (CCI) ChartProQR Therapeutics BV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ProQR Therapeutics BV. The current cmo is -44.60328934.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
ProQR Therapeutics BV Daily Chande Momentum Oscillator (CMO) ChartProQR Therapeutics BV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ProQR Therapeutics BV. The current willr is -87.5.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
ProQR Therapeutics BV Daily Williams %R ChartProQR Therapeutics BV Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ProQR Therapeutics BV.

ProQR Therapeutics BV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ProQR Therapeutics BV. The current atr is 0.09312298.

ProQR Therapeutics BV Daily Average True Range (ATR) ChartProQR Therapeutics BV Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ProQR Therapeutics BV. The current obv is 109,306,055.

ProQR Therapeutics BV Daily On-Balance Volume (OBV) ChartProQR Therapeutics BV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ProQR Therapeutics BV. The current mfi is 36.13.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
ProQR Therapeutics BV Daily Money Flow Index (MFI) ChartProQR Therapeutics BV Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ProQR Therapeutics BV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-05-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-06-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-06-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-03STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

ProQR Therapeutics BV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ProQR Therapeutics BV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.063
Ma 20Greater thanMa 501.742
Ma 50Greater thanMa 1001.867
Ma 100Greater thanMa 2002.004
OpenGreater thanClose1.630
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Proqr with someone you think should read this too:
  • Are you bullish or bearish on Proqr? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Proqr? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ProQR Therapeutics BV

I send you an email if I find something interesting about ProQR Therapeutics BV.


Stay informed about ProQR Therapeutics BV.

Receive notifications about ProQR Therapeutics BV in your mailbox!